That we will.
Your theory is as reasonably as any other. In fact my very first suspicion, was that the BOD wants a quick resolution and the opportunity to bank some money while MT wanted to take it further. Was there any mention of Pre Clinical work on other conditions in the Quarterly ? I cant be bothered checking at the moment.
No matter what shenanigans may be going on, ODD will make Pharmaust a very attractive proposition.
Just guessing everyone, so don't take these comments to seriously. But it would explain a host of curiosities.
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst, page-1274
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.5¢ |
Change
-0.010(4.26%) |
Mkt cap ! $89.08M | |||
| Open | High | Low | Value | Volume |
| 23.5¢ | 23.5¢ | 22.0¢ | $170.5K | 749.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 34313 | 22.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.5¢ | 24444 | 2 |
View Market Depth
| Last trade - 16.10pm 14/06/2024 (20 minute delay) ? |
|
|||||
|
Last
22.5¢ |
Change
-0.010 ( 6.25 %) |
||||
| Open | High | Low | Volume | ||
| 23.0¢ | 23.0¢ | 22.0¢ | 246904 | ||
| Last updated 15.57pm 14/06/2024 ? | |||||
| PAA (ASX) Chart |